CPDR is a program of the Uniformed Services University of the Health Sciences
and the Henry M. Jackson Foundation for the Advancement of Military Medicine

< Publications Archive

> 2007 Publications

1-10  

 

11. Silencing of Lactotransferrin Expression by Methylation in Prostate Cancer Progression
Shaheduzzaman S, Vishwanath A, Furusato B, Cullen J, Chen Y, Bañez L, Nau M, Ravindranath L, Kim KH, Mohammed A, Chen Y, Ehrich M, Srikantan V, Sesterhenn IA, McLeod DG, Vahey M, Petrovics G, Dobi A, Srivastava S.
Cancer Biol Ther. 2007 Jul 20;6(7) [Epub ahead of print]
Abstract

 

12. A role for DNA methylation in regulating the growth suppressor PMEPA1 gene in prostate cancer
Richter E, Masuda K, Cook C, Ehrich M, Tadese AY, Li H, Owusu A, Srivastava S, Dobi A.
Epigenetics. 2007 Apr-Jun;2(2):100-9. Epub 2006 Dec 27.
Abstract

 

13. Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality
D'Amico AV, McLeod DG, Carroll PR, Cullen J, Chen MH.
Cancer. 2007 Apr 1;109(7):1290-5.
Abstract

 

14. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens
Miki J, Furusato B, Li H, Gu Y, Takahashi H, Egawa S, Sesterhenn IA, McLeod DG, Srivastava S, Rhim JS.
Cancer Res. 2007 Apr 1;67(7):3153-61.
Abstract

 

15. Sarcoidosis of the prostate
Furusato B, Koff S, McLeod DG, Sesterhenn IA.
J Clin Pathol. 2007 Mar;60(3):325-6.
Abstract

 

16. Androgen receptor and prostate cancer
Richter E, Srivastava S, Dobi A.
Prostate Cancer Prostatic Dis. 2007;10(2):114-8. Epub 2007 Feb 13.
Abstract